Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax (Nasdaq: NVAX), a biotechnology company specializing in vaccines, announced participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. The event will feature discussions about its COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John Trizzino. A replay of the session will be available on the company’s website for 90 days. Novavax aims to combat serious infectious diseases through innovative vaccines and is advancing its COVID-19 and NanoFlu vaccine candidates in clinical trials.
Novavax, Inc. (Nasdaq: NVAX) announced that Gregory M. Glenn, M.D., will present on NVX-CoV2373, its COVID-19 vaccine candidate, at the 2021 International Society for Vaccines Virtual Congress on May 25, 2021. The presentation will cover safety, efficacy, and immunogenicity data. A recent analysis from Phase 3 trials in the U.K. shows approximately 90% efficacy against COVID-19, with impressive results against variants. NVX-CoV2373 utilizes Novavax's proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to enhance immune response.
Novavax, Inc. (Nasdaq: NVAX) has signed a non-binding memorandum of understanding (MoU) with Korea's Ministry of Health and Welfare and SK bioscience to enhance cooperation in developing and manufacturing vaccines, including NVX-CoV2373, its COVID-19 vaccine candidate. This partnership underscores Novavax's commitment to ensuring global vaccine access. The MoU builds on existing collaboration and aims to explore new vaccine products for COVID-19 variants and an influenza-COVID-19 combination. SK bioscience has initiated the regulatory submission process for NVX-CoV2373 in South Korea.
On May 21, 2021, Novavax (Nasdaq: NVAX) was awarded 'Life Sciences Company of the Year' by the Maryland Tech Council, with CEO Stanley C. Erck receiving 'Life Sciences Chief Executive Officer of the Year.' The awards recognize Novavax's role in accelerating equitable access to COVID-19 vaccines. NVX-CoV2373, their protein-based vaccine candidate, has shown efficacy in trials, including 96.4% against the original strain and 86.3% against the B.1.1.7 variant. The U.S. and Mexico PREVENT-19 trial began in December 2020, further solidifying their commitment to global health.
Novavax, Inc. (NASDAQ: NVAX) reported significant progress in Q1 2021, achieving 96.4% efficacy against the original COVID-19 strain and 86.3% against the B.1.1.7 variant in a Phase 3 UK trial. The company reported revenues of $447 million compared to $3 million in Q1 2020, but incurred a net loss of $223 million per share, up from $26 million a year earlier. Novavax also bolstered its manufacturing capacity with plans to produce 100 million doses per month by Q3 2021 and secured several global agreements for vaccine distribution.
Novavax (Nasdaq: NVAX) announced promising results from a preclinical study of its combination vaccine, NanoFlu/NVX-CoV2373, which targets both influenza and COVID-19. The vaccine demonstrated strong immune responses against influenza A, B, and SARS-CoV-2, with clinical trials expected to start by year-end. The study showed that the combination vaccine elicited comparable antibody responses to individual vaccines and effectively protected hamsters from SARS-CoV-2 infection. Novavax aims to address public health needs with this novel vaccine strategy.
Novavax has finalized an advance purchase agreement (APA) with Gavi to supply 350 million doses of its COVID-19 vaccine, NVX-CoV2373, to the COVAX Facility starting Q3 2021. In total, 1.1 billion doses will be distributed, with the Serum Institute of India handling the remainder. The APA, supported by CEPI's investment of nearly $400 million, aims to enhance equitable vaccine access. Novavax's CEO emphasized the importance of collaboration for global health, while Gavi highlighted the deal as a major step towards delivering 2 billion doses in 2021.
Novavax, Inc. (Nasdaq: NVAX) announced the publication of initial results from a Phase 2b clinical trial of its NVX-CoV2373 COVID-19 vaccine in South Africa, appearing in the New England Journal of Medicine. The vaccine achieved an overall efficacy of 49%, with 60% efficacy among healthy adults without HIV. Despite the presence of the B.1.351 variant, severe cases occurred only in the placebo group. The data suggest the need for ongoing evaluation against variants. The trial emphasizes the vaccine's safety and supports its ongoing development for pandemic response.
Novavax, Inc. (Nasdaq: NVAX) has initiated a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, a COVID-19 vaccine candidate. The PREVENT-19 trial will now evaluate up to 3,000 adolescents aged 12-17 across 75 U.S. sites. Participants will receive either the vaccine or placebo in two doses. The study aims to further assess safety and efficacy data established in adults. Results thus far indicate robust immune responses, positioning Novavax as a key player in the global vaccination effort against COVID-19.
Novavax, Inc. (Nasdaq: NVAX) will report its Q1 2021 financial results and operational highlights on May 10, 2021, after U.S. market close. A conference call will occur at 4:30 p.m. ET, with dial-in options available for domestic and international participants. Details for the call, including replay options starting May 10 at 7:30 p.m. ET, are provided in the press release. Novavax is advancing its COVID-19 vaccine candidate and its quadrivalent influenza vaccine towards regulatory submission, utilizing its proprietary technology to address global health needs.
